Illumina are to purchase Pacific Biosciences for $1.2 billion. Illumina already dominate the short-read NGS market and this will give them a high performance long-read technology as well, useful for de novo sequencing and other applications. It is possible there might be competition law/antitrust hurdles to clear, although the technologies tend to serve different applications so this may not prove a serious concern.